Amdocs (DOX) Looks Misread As Recurring Revenue Keeps The Undervalued Narrative Alive

Amdocs (DOX) is back in focus after a recent share move that leaves the stock trading around $59.81, with investors weighing its telecom software footprint against mixed short and longer term return figures.

Recent trading has been choppy for Amdocs, with the share price down over the past week but posting a 30 day share price return of 2.08% and a 90 day share price return of 6.73%, set against a much weaker year to date share price return and a 1 year total shareholder return that has declined 26.32%. This suggests that momentum may be trying to rebuild after a tougher stretch.

Scan how Amdocs compares with other potential rebound stories by reviewing our hand picked 49 high quality undervalued stocks, which pairs solid fundamentals with discounted share prices.

Amdocs looks like a solid telecom software specialist on paper, yet the share price reset and long term return drag raise a simple question: Is this business now on sale or fairly marked where it trades today?

Most Popular Narrative: 27.1% Undervalued

Amdocs is framed as materially undervalued in the most followed narrative, which sets a fair value of $82.03 against the recent close around $59.81.

Financially, the company is characterized by strong recurring revenue streams, highlighted by a high renewal rate for managed services, which account for approximately 65% of total revenue, and a substantial 12-month backlog of $4.28 billion. This stability allows the company to pursue a disciplined capital allocation strategy, featuring consistent dividend growth and significant share repurchases.

Read the complete narrative.

Curious what sits underneath that $82.03 figure. The narrative leans heavily on recurring cash generation, margin resilience and a specific growth path baked into its models. The exact mix of revenue expansion, profitability and discount rate assumptions is where the story really gets interesting.

Result: Fair Value of $82.03 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, Amdocs faces real pressure if telecom clients slow spending on large projects or if its GenAI products fail to gain meaningful customer adoption.

Find out about the key risks to this Amdocs narrative.

Next Steps

If the mixed mood around Amdocs leaves you on the fence, look at the numbers directly, weigh both sides, and review the 4 key rewards and 1 important warning sign.

Looking for more Amdocs-sized opportunities?

If Amdocs has you thinking about what else might be mispriced, do not stop here. Cast a wider net and pressure test your ideas.

• Target potential bargains that pair resilient operations with discounted valuations through the 49 high quality undervalued stocks.
• Protect your downside first by focusing on 80 resilient stocks with low risk scores that aim to keep volatility and risk in check.
• Hunt for future leaders hiding in plain sight by scanning 17 high quality undiscovered gems before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com